RTP Mobile Logo
Oncology Today with Dr Neil Love: Key Presentations on Lung Cancer from the 2021 ASCO Annual Meeting (Video Presentation)
Released August 2021

Featuring an interview with Dr Joel Neal. Published August 16, 2021. (Video Presentation)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancers.

    LEARNING OBJECTIVES

    • Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic non-small cell lung cancer (NSCLC), and evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches to (neo)adjuvant therapy.
    • Review recent therapeutic advances with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or other immunotherapies for metastatic NSCLC, and discern how these approaches can be optimally employed in disease management.
    • Appraise updated data on the efficacy of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
    • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
    • Assess the efficacy of commercially available ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy.
    • Recognize other oncogenic pathways (ie, RET, MET, HER2, KRAS, ROS1) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
    • Design an optimal approach to the clinical care of patients with small cell lung cancer, considering available and emerging clinical trial findings.
    • Assess the biologic rationale for ongoing clinical trials evaluating novel agents and strategies for NSCLC, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.25 (audio) and 1 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayPostASCOLung21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OncologyTodayPostASCOLung21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayPostASCOLung21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OncologyTodayPostASCOLung21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Joel W Neal, MD, PhD
    Associate Professor of Medicine
    Division of Oncology, Department of Medicine
    Stanford Cancer Institute
    Stanford University
    Palo Alto, California

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Calithera Biosciences, Exelixis Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Nektar, Novartis, Takeda Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, and Novartis.

    Release date: August 2021
    Expiration date: August 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):